Cargando…

Limb-salvage surgery offers better five-year survival rate than amputation in patients with limb osteosarcoma treated with neoadjuvant chemotherapy. A systematic review and meta-analysis

BACKGROUND: Osteosarcoma is the most common primary bone sarcoma. Currently, the main treatment option for high-grade osteosarcomas is neoadjuvant chemotherapy, followed by surgical resection of the lesion and adjuvant chemotherapy. Limb salvage surgery (LSS) and amputation are the main surgical tec...

Descripción completa

Detalles Bibliográficos
Autores principales: Papakonstantinou, Evgenia, Stamatopoulos, Alexandros, I Athanasiadis, Dimitrios, Kenanidis, Efstathios, Potoupnis, Michael, Haidich, Anna-Bettina, Tsiridis, Eleftherios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567946/
https://www.ncbi.nlm.nih.gov/pubmed/33088699
http://dx.doi.org/10.1016/j.jbo.2020.100319
_version_ 1783596430556921856
author Papakonstantinou, Evgenia
Stamatopoulos, Alexandros
I Athanasiadis, Dimitrios
Kenanidis, Efstathios
Potoupnis, Michael
Haidich, Anna-Bettina
Tsiridis, Eleftherios
author_facet Papakonstantinou, Evgenia
Stamatopoulos, Alexandros
I Athanasiadis, Dimitrios
Kenanidis, Efstathios
Potoupnis, Michael
Haidich, Anna-Bettina
Tsiridis, Eleftherios
author_sort Papakonstantinou, Evgenia
collection PubMed
description BACKGROUND: Osteosarcoma is the most common primary bone sarcoma. Currently, the main treatment option for high-grade osteosarcomas is neoadjuvant chemotherapy, followed by surgical resection of the lesion and adjuvant chemotherapy. Limb salvage surgery (LSS) and amputation are the main surgical techniques; however, controversy still exists concerning the best surgical method. Our meta-analysis compared the effectiveness of LSS and amputation combined with neoadjuvant chemotherapy in patients with limb osteosarcoma, in terms of 5-year overall survival (OS), 5-year disease-free survival (DFS) and local recurrence rate. METHODS: Following the established methodology of PRISMA guidelines, a literature search was conducted in PubMed, Cochrane, Google Scholar from 1975 until January 2020. Two independent reviewers evaluated the study quality based on the Newcastle-Ottawa scale. Odds ratio and 95% confidence interval of the OS, DFS and local recurrence rate were calculated. RESULTS: Thirteen studies were finally included with a total of 2884 patients; 1986 patients undergone LSS and 898 amputations. Five-year overall survival was almost 2-fold in patients treated with LSS than those treated with amputation (OR: 1.99; 95% CI: 1.35–2.93; I(2) = 74%, p < 0.001). No difference was found in 5-year DFS between LSS patients and amputees (OR: 1.24; 95% CI: 0.55–2.79; I(2) = 67%, p = 0.01). The odds of local recurrence was numerically higher in LSS compared to amputation but not statistically significant (OR: 2.29; 95% CI: 0.95–5.53; I(2) = 47%, p = 0.05). However, the included studies did not clearly define differences in the stages of patients of the two groups. CONCLUSION: Our study demonstrated that in patients with limb osteosarcoma treated with neoadjuvant chemotherapy, LSS is associated with a higher 5-year overall survival and the odds of local recurrence may be increased but these results should be interpreted with caution due to high heterogeneity.
format Online
Article
Text
id pubmed-7567946
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-75679462020-10-20 Limb-salvage surgery offers better five-year survival rate than amputation in patients with limb osteosarcoma treated with neoadjuvant chemotherapy. A systematic review and meta-analysis Papakonstantinou, Evgenia Stamatopoulos, Alexandros I Athanasiadis, Dimitrios Kenanidis, Efstathios Potoupnis, Michael Haidich, Anna-Bettina Tsiridis, Eleftherios J Bone Oncol Review Article BACKGROUND: Osteosarcoma is the most common primary bone sarcoma. Currently, the main treatment option for high-grade osteosarcomas is neoadjuvant chemotherapy, followed by surgical resection of the lesion and adjuvant chemotherapy. Limb salvage surgery (LSS) and amputation are the main surgical techniques; however, controversy still exists concerning the best surgical method. Our meta-analysis compared the effectiveness of LSS and amputation combined with neoadjuvant chemotherapy in patients with limb osteosarcoma, in terms of 5-year overall survival (OS), 5-year disease-free survival (DFS) and local recurrence rate. METHODS: Following the established methodology of PRISMA guidelines, a literature search was conducted in PubMed, Cochrane, Google Scholar from 1975 until January 2020. Two independent reviewers evaluated the study quality based on the Newcastle-Ottawa scale. Odds ratio and 95% confidence interval of the OS, DFS and local recurrence rate were calculated. RESULTS: Thirteen studies were finally included with a total of 2884 patients; 1986 patients undergone LSS and 898 amputations. Five-year overall survival was almost 2-fold in patients treated with LSS than those treated with amputation (OR: 1.99; 95% CI: 1.35–2.93; I(2) = 74%, p < 0.001). No difference was found in 5-year DFS between LSS patients and amputees (OR: 1.24; 95% CI: 0.55–2.79; I(2) = 67%, p = 0.01). The odds of local recurrence was numerically higher in LSS compared to amputation but not statistically significant (OR: 2.29; 95% CI: 0.95–5.53; I(2) = 47%, p = 0.05). However, the included studies did not clearly define differences in the stages of patients of the two groups. CONCLUSION: Our study demonstrated that in patients with limb osteosarcoma treated with neoadjuvant chemotherapy, LSS is associated with a higher 5-year overall survival and the odds of local recurrence may be increased but these results should be interpreted with caution due to high heterogeneity. Elsevier 2020-09-15 /pmc/articles/PMC7567946/ /pubmed/33088699 http://dx.doi.org/10.1016/j.jbo.2020.100319 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review Article
Papakonstantinou, Evgenia
Stamatopoulos, Alexandros
I Athanasiadis, Dimitrios
Kenanidis, Efstathios
Potoupnis, Michael
Haidich, Anna-Bettina
Tsiridis, Eleftherios
Limb-salvage surgery offers better five-year survival rate than amputation in patients with limb osteosarcoma treated with neoadjuvant chemotherapy. A systematic review and meta-analysis
title Limb-salvage surgery offers better five-year survival rate than amputation in patients with limb osteosarcoma treated with neoadjuvant chemotherapy. A systematic review and meta-analysis
title_full Limb-salvage surgery offers better five-year survival rate than amputation in patients with limb osteosarcoma treated with neoadjuvant chemotherapy. A systematic review and meta-analysis
title_fullStr Limb-salvage surgery offers better five-year survival rate than amputation in patients with limb osteosarcoma treated with neoadjuvant chemotherapy. A systematic review and meta-analysis
title_full_unstemmed Limb-salvage surgery offers better five-year survival rate than amputation in patients with limb osteosarcoma treated with neoadjuvant chemotherapy. A systematic review and meta-analysis
title_short Limb-salvage surgery offers better five-year survival rate than amputation in patients with limb osteosarcoma treated with neoadjuvant chemotherapy. A systematic review and meta-analysis
title_sort limb-salvage surgery offers better five-year survival rate than amputation in patients with limb osteosarcoma treated with neoadjuvant chemotherapy. a systematic review and meta-analysis
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567946/
https://www.ncbi.nlm.nih.gov/pubmed/33088699
http://dx.doi.org/10.1016/j.jbo.2020.100319
work_keys_str_mv AT papakonstantinouevgenia limbsalvagesurgeryoffersbetterfiveyearsurvivalratethanamputationinpatientswithlimbosteosarcomatreatedwithneoadjuvantchemotherapyasystematicreviewandmetaanalysis
AT stamatopoulosalexandros limbsalvagesurgeryoffersbetterfiveyearsurvivalratethanamputationinpatientswithlimbosteosarcomatreatedwithneoadjuvantchemotherapyasystematicreviewandmetaanalysis
AT iathanasiadisdimitrios limbsalvagesurgeryoffersbetterfiveyearsurvivalratethanamputationinpatientswithlimbosteosarcomatreatedwithneoadjuvantchemotherapyasystematicreviewandmetaanalysis
AT kenanidisefstathios limbsalvagesurgeryoffersbetterfiveyearsurvivalratethanamputationinpatientswithlimbosteosarcomatreatedwithneoadjuvantchemotherapyasystematicreviewandmetaanalysis
AT potoupnismichael limbsalvagesurgeryoffersbetterfiveyearsurvivalratethanamputationinpatientswithlimbosteosarcomatreatedwithneoadjuvantchemotherapyasystematicreviewandmetaanalysis
AT haidichannabettina limbsalvagesurgeryoffersbetterfiveyearsurvivalratethanamputationinpatientswithlimbosteosarcomatreatedwithneoadjuvantchemotherapyasystematicreviewandmetaanalysis
AT tsiridiseleftherios limbsalvagesurgeryoffersbetterfiveyearsurvivalratethanamputationinpatientswithlimbosteosarcomatreatedwithneoadjuvantchemotherapyasystematicreviewandmetaanalysis